AstraZeneca hit by generics as revenues drop

Adam Hignett
ASTRAZENECA ended an interesting year in a downbeat manner as fourth quarter results revealed the company sustained a loss during the three months ending 31 December.

Last year saw the UK’s second largest pharmaceutical company successfully fend off a £69bn takeover bid by US drugs giant Pfizer and get approval for a record six new products.

However, the company faced pressure from increased competition from cheaper generic copies of its older drugs which hit sales and profits, a situation the company admitted was likely to continue for the duration of 2015 before any newer products hit the shelves.

Revenue for the fourth quarter came in at $6.8bn, a two per cent decrease in actual terms on the same period in 2013.

Overall revenue for the year increased one per cent to $26bn. Profit before tax saw a sharp decline of 43 per cent for the fourth quarter compared to the previous year, to come in at a loss of $580m, leading earnings per share to decline by 38 per cent to record a small loss of 0.25 per cent.

Despite this, the board reaffirmed its commitment to the company’s dividend policy, declaring a second interim dividend of $1.90 per share, bringing the total dividend to $2.80.

Pascal Soriot, chief executive officer, described 2014 as a remarkable year, adding: “We achieved a record six product approvals as we accelerated our pipeline across all main therapy areas, with growth platforms now contributing over half of our revenues.

Shares ended down 3.4 per cent.

Related articles